Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Use of Tranexamic Acid in Oncologic Lower Limb Endoprosthetic Reconstruction: A Retrospective Analysis of 617 Cases

  • By

  • Stephen W. Chenard

  • Akhil Rekulapelli

  • Riley S. Gilbertson

  • Connor S. Charton

  • William F. Hefley

  • Michael J. Colello

  • Jennifer L. Halpern

  • Herbert S. Schwartz

  • Daniel J. Johnson

  • Jonathan G. Schoenecker

  • Joshua M. Lawrenz

  • June 1, 2026

Share

Clinical Scorecard: Use of Tranexamic Acid in Oncologic Lower Limb Endoprosthetic Reconstruction: A Retrospective Analysis of 617 Cases

At a Glance

CategoryDetail
ConditionOncologic Lower Limb Endoprosthetic Reconstruction
Key MechanismsTranexamic acid (TXA) is an antifibrinolytic drug that reduces blood loss and transfusion rates.
Target PopulationPatients undergoing lower extremity endoprosthetic reconstruction for oncologic indications.
Care SettingTertiary academic hospital

Key Highlights

  • TXA reduces blood loss and transfusion rates in orthopedic surgeries.
  • Patients with cancer have a ninefold increased risk of venous thromboembolism (VTE).
  • Concerns exist regarding TXA's safety in hypercoagulable cancer patients.
  • The study included 617 patients, with 166 receiving TXA.
  • No significant differences in major preoperative medical comorbidities between TXA and non-TXA groups.

Guideline-Based Recommendations

Diagnosis

  • Evaluate patients for oncologic indications prior to endoprosthetic reconstruction.

Management

  • Consider TXA administration to reduce blood loss in oncologic surgeries.

Monitoring & Follow-up

  • Monitor for thromboembolic complications in patients receiving TXA.

Risks

  • Assess the risk of VTE in patients with cancer when using TXA.

Patient & Prescribing Data

617 patients undergoing lower extremity endoprosthetic reconstruction.

TXA was administered in various forms, with no significant differences in demographics or comorbidities between TXA-treated and non-TXA groups.

Clinical Best Practices

  • Utilize TXA to minimize blood loss in oncologic surgeries while monitoring for VTE risks.
  • Ensure thorough preoperative assessment of patients' thromboembolic history.

Related Resources & Content

Original Source(s)

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

  • by Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz

  • June 1, 2026

Related Content

Correction: Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer

Moving Cancer Survivorship Into Routine Care—Why Are We Still Not Ready for Change?

Updated ASTRO Guideline Reflects a New Era for Radiation Therapy in Pancreatic Cancer

An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.

  • by

  • August 14, 2026

  • 6 min